Dynavax Technologies Sees Unusually Large Options Volume (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders bought 3,017 call options on the stock. This represents an increase of 803% compared to the average volume of 334 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and cut their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Trading Down 0.3 %

Shares of DVAX stock traded down $0.04 during mid-day trading on Friday, hitting $13.68. 1,368,915 shares of the company's stock were exchanged, compared to its average volume of 2,136,231. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of 76.00 and a beta of 1.23. The stock has a 50-day simple moving average of $13.35 and a two-hundred day simple moving average of $12.49. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Remove Ads

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Equities analysts expect that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. raised its holdings in shares of Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock worth $225,000 after purchasing an additional 771 shares during the period. Summit Investment Advisors Inc. increased its position in Dynavax Technologies by 7.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock worth $176,000 after purchasing an additional 904 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares during the period. Sanctuary Advisors LLC lifted its position in Dynavax Technologies by 6.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock valued at $245,000 after buying an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 1,169 shares during the period. Institutional investors and hedge funds own 96.96% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.